Advertisement

Why New COVID Strains May Mean More Revenue for Pfizer and Moderna

In this Motley Fool Live video, recorded on Feb. 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss how Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA), and others are faring, how they plan to deal with new variants, and what all of this means for revenue. Corinne Cardina: There has been a lot of different research about which vaccines, how they're holding up against different variants.